Towards Healthcare
HIV Drugs Market Size and Trends Report (2024 - 2032)

HIV Drugs Market Size Envisioned at USD 49.68 Billion by 2032

The report covers HIV Drugs Market Shares and Companies such as ViiV Healthcare, Gilead Sciences, Inc., and Janssen Pharmaceuticals, Inc., among others. It encompasses various drug types including Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Integrase Inhibitors, Entry and Fusion Inhibitors and Combination Class Drugs. These drugs are distributed through hospital, retail and online pharmacies across different geographical regions including North America, Europe, Asia Pacific, Middle East and Africa and South America. The report offers the value (in USD Billion) for the above segments.

Introduction

  • Research Objective
  • Scope of the Study
  • Definition and Taxonomy

Research Methodology

  • Research Approach
  • Data Sources
  • Assumptions

Executive Summary

  • Synopsis
  • Analyst Recommendations

Market Overview 

  • Market Dynamics
    • Market Drivers
    • Market Restraints
    • Market Opportunities
  • Value Chain Analysis
    • Raw Material Sourcing
    • Manufacturing Process
    • Logistics & Transportation
    • Buyer Preferences
  • Trends
    • Market Trends
    • Technological Trends
  • Porter’s Five Forces Analysis
    • Bargaining Power of Suppliers
    • Bargaining Power of Buyers
    • Threat of Substitute
    • Threat of New Entrants
    • Degree of Competition
  • PESTLE Analysis for 5 Leading Countries
    • Regulatory Framework for Leading Countries/Regions
    • Supply Demand Analysis
    • Production & Consumption Statistics
    • Export Import Statistics
    • Price Trend Analysis

Global HIV Drugs Market Assessment

  • Overview
  • Global HIV Drugs Market Size Value (US$) and Volume (Billion Tons), by Drug Type (2021 – 2033)
    • Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
    • Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
    • Protease Inhibitors (PIs)
    • Integrase Inhibitors
    • Entry and Fusion Inhibitors
    • Combination Class Drugs
  • Global HIV Drugs Market Size Value (US$) and Volume (Billion Tons), by Distribution Channel (2021 – 2033)
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global HIV Drugs Market Size Value (US$) and Volume (Billion Tons), by Geography (2021 – 2033)
    • North America
    • Europe
    • Asia Pacific
    • Middle East and Africa
    • South America

North America HIV Drugs Market Assessment

  • Overview
  • North America HIV Drugs Market Size Value (US$) and Volume (Billion Tons), by Drug Type (2021 – 2033)
    • Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
    • Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
    • Protease Inhibitors (PIs)
    • Integrase Inhibitors
    • Entry and Fusion Inhibitors
    • Combination Class Drugs
  • North America HIV Drugs Market Size Value (US$) and Volume (Billion Tons), by Distribution Channel (2021 – 2033)
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies

Europe HIV Drugs Market Assessment

  • Overview
  • Europe HIV Drugs Market Size Value (US$) and Volume (Billion Tons), by Drug Type (2021 – 2033)
    • Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
    • Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
    • Protease Inhibitors (PIs)
    • Integrase Inhibitors
    • Entry and Fusion Inhibitors
    • Combination Class Drugs
  • Europe HIV Drugs Market Size Value (US$) and Volume (Billion Tons), by Distribution Channel (2021 – 2033)
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies

Asia Pacific HIV Drugs Market Assessment

  • Overview
  • Asia Pacific HIV Drugs Market Size Value (US$) and Volume (Billion Tons), by Drug Type (2021 – 2033)
    • Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
    • Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
    • Protease Inhibitors (PIs)
    • Integrase Inhibitors
    • Entry and Fusion Inhibitors
    • Combination Class Drugs
  • Asia Pacific HIV Drugs Market Size Value (US$) and Volume (Billion Tons), by Distribution Channel (2021 – 2033)
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies

Middle East and Africa HIV Drugs Market Assessment

  • Overview
  • Middle East and Africa HIV Drugs Market Size Value (US$) and Volume (Billion Tons), by Drug Type (2021 – 2033)
    • Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
    • Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
    • Protease Inhibitors (PIs)
    • Integrase Inhibitors
    • Entry and Fusion Inhibitors
    • Combination Class Drugs
  • Middle East and Africa HIV Drugs Market Size Value (US$) and Volume (Billion Tons), by Distribution Channel (2021 – 2033)
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies

South America HIV Drugs Market Assessment

  • Overview
  • South America HIV Drugs Market Size Value (US$) and Volume (Billion Tons), by Drug Type (2021 – 2033)
    • Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
    • Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
    • Protease Inhibitors (PIs)
    • Integrase Inhibitors
    • Entry and Fusion Inhibitors
    • Combination Class Drugs
  • South America HIV Drugs Market Size Value (US$) and Volume (Billion Tons), by Distribution Channel (2021 – 2033)
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies

Company Profiles

  • ViiV Healthcare
    • Company Overview
    • Geographic Footprints
    • Financial Performance
    • Product Portfolio
    • SWOT Analysis
    • R&D Efforts
    • Recent Developments & Strategic Collaborations
      • Product Launch/M&A/Technical Collaboration
  • Gilead Sciences, Inc.
  • Janssen Pharmaceuticals, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Mylan Pharmaceuticals Inc.
  • Theratechnologies Inc.
  • Boehringer Ingelheim International GmbH
  • Cipla Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Merck & Co., Inc.

Conclusion & Recommendations

  • Insight Code: 5131
  • No. of Pages: 150+
  • Format: PDF/PPT/Excel
  • Published: March 2024
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2022
  • Base Year: 2023
  • Estimated Years: 2024-2033

About The Author

Deepa has certified the degree of Master’s in Pharmacy in the Pharmaceutical Quality Assurance department from Dr D.Y. Patil College of Pharmacy. Her research is focused on the healthcare industry. She is the author or co-author of four Review Articles, which include Solid dispersion a strategic method for poorly soluble drugs and solubility improvement techniques for poorly soluble drugs, Herbal Drugs Used In Treatment Of Cataracts, Nano sponges And Their Application in Cancer Prevention and Ayurvedic Remedies of Peptic ulcer. She has also published a Research Article on the Formulation and Evaluation of Mucoadhesive Tablets of Miconazole cocrystal which was published in GIS Science Journal Volume 9 Issue 8. Her passion for secondary research and desire to take on the challenge of solving unresolved issues is making her flourish is the in the research sector.

FAQ's

Common symptoms of HIV include fever, fatigue, sore throat, and swollen lymph nodes. As the virus progresses, symptoms may worsen, including weight loss, chronic diarrhea, night sweats, and recurrent infections. It is important to note that some people may not experience any symptoms for years after being infected with HIV. Early detection through testing is crucial for timely intervention and treatment.

One significant hurdle in the HIV drug market is the development of drug resistance, where the virus mutates and becomes less susceptible to the effects of antiretroviral drugs. This resistance challenges maintaining effective treatment regimens and requires ongoing research and development efforts to stay ahead of the virus.

North America, particularly the United States, leads the market for HIV drugs due to factors such as high healthcare spending, robust research and development infrastructure, and widespread access to treatment and care services.

World Health Organization, HHS.gov., Centers for Disease Control and Prevention, HIV.gov., National Institute of Health

Warning: include(report-detail-graphs.php): failed to open stream: No such file or directory in /home/thealthcre/public_html/report-toc.php on line 509

Warning: include(): Failed opening 'report-detail-graphs.php' for inclusion (include_path='.:/opt/cpanel/ea-php74/root/usr/share/pear') in /home/thealthcre/public_html/report-toc.php on line 509